Aviceda Therapeutics has launched biotech financing in 2025 with a $207.5m raise to advance its lead drug for geographic atrophy, a sight-threatening disease, into pivotal trials.
The Series C round, co-led by Omega Funds and TCGX, will support the ongoing phase 2/3 SIGLEC trial of AVD-104 for geographic atrophy linked to age-related macular degeneration.
The trial is expected to deliver results in the second half of the year, with funding also allocated to a phase 3 programme if progress stays on track.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The funding round also saw participation from investment firms including Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, and Digitalis Ventures.
Source: Pharmaphorum
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...